The micro-cap company, Heat Biologics Inc (NASDAQ:HTBX) recorded a climb during the last trading session after release of positive preclinical data. The company presented the data at a Keystone Symposia in Banff, Canada, discussing the subject “Tumor Immunology — Multidisciplinary Science Driving Combination Therapy.” The company said that it had successfully incorporated T-cell costimulatory fusion proteins into its gp96-ig vaccine platform.
Lowered Risk And Cost Of Therapy
The company which is focussed on developing cancer-based immunotherapies said that its preclinical trial was aimed to bring a new combination immunotherapy. The therapy was formed combining Heat Biologics Inc (NASDAQ:HTBX)’s gp96-ig vaccine and individual T-cell costimulatory fusion proteins simultaneously. While presenting the data, the company’s Taylor Schreiber, MD, Ph.D., Vice President of Research and Development said that the results are exciting. He said that they had been able to construct a second-generation vaccine, containing both T-cel fusion protein and gp96-ig vaccine.
Schreiber further added that the new immunotherapy has the benefit of combination immunotherapy while it does not contain systemic toxicity risks, which are associated with antibodies. Also, the novel therapy will give cost efficiency, which otherwise is a factor to be considered while combining multiple independent products.
Several Combinations Tested
Heat Biologics Inc (NASDAQ:HTBX) further elaborated the process of combining gp96-Ig vaccination and OX40L-Fc fusion protein agonists, which was achieved after undergoing several constructs. It was found that the combination of gp96-Ig and OX40L-Fc provided highest benefit that boosted activation of antigen-specific CD8+ T-cells, thereby reducing cost of therapy and associated risks. The company briefed that George Fromm, Ph.D., Aditi Goyal, Neal Schilling, Ph.D., and Taylor H. Schreiber, MD, Ph.D. undertook the study and arrived at the disclosed conclusion.
Following the data presentation report, the shares of Heat Biologics Inc (NASDAQ:HTBX) reported an increase of 5.73%, indicating a $0.30 gain to close at $5.47.
is in a bear market for over a year. The sharp decline has stopped after taking the price down to $4 levels from the heights of $15 but the bearish phase is not over yet. Fresh lows are not coming but no higher highs have been registered yet. The price contraction suggests that all the rallies and decline in this phase are meaningless from the larger perspective. Unless the price breaks beyond either $8 or $3.50, the movements can be ignored.